Loading
Therorna builds medicines from circular RNA, a more stable form of RNA. Its first cancer product is a therapeutic vaccine for people whose cancer is driven by the HPV-16 virus and has come back or spread.
Therorna Inc. (Yuanyin (Beijing) Biotechnology Co., Ltd.), founded in April 2021 according to the company, is based in Haidian District, Beijing, with a site in the Shanghai Free Trade Zone. It develops preventive and therapeutic medicines on a circular RNA (circRNA) platform. Its phase 1 dose-escalation study (NCT07081984) tests TI-0093, which the registry describes as a therapeutic tumour vaccine given by intramuscular injection on five occasions, in recurrent or metastatic HPV-16 positive solid tumours including head and neck squamous cell carcinoma and cervical cancer, at a site in Shanghai. Its first registered cancer trial, NCT07081984, was posted on ClinicalTrials.gov in July 2025.
Shares HPV-positive oropharyngeal cancer, Recurrent or metastatic head and neck squamous cell carcinoma.
Shares HPV-positive oropharyngeal cancer, Recurrent or metastatic head and neck squamous cell carcinoma.
Shares HPV-positive oropharyngeal cancer, Recurrent or metastatic head and neck squamous cell carcinoma.
Shares HPV-positive oropharyngeal cancer, Recurrent or metastatic head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/